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Introduction
Coronary artery disease (CAD) is the most important cause of 
cardiovascular adverse events. Despite modern treatment, the 
mortality caused by CAD is still increasing.1) Diabetes, hypertension, 
hyperlipidemia, and smoking are risk factors of CAD that can be 
controlled. Genetic features are an important and unchangeable 
risk factor for CAD pathogenesis. Recently, studies investigating 
the relationship between CAD and genetic predisposition have 
been increasing.2-4) Studies showed that 40% to 60% of the risk for 
CAD is related to genetic predisposition.5) Until now, more than 30 
genetic risk variants for CAD have been identified in genome-wide 
association studies (GWAS).6) Among them, association of 4 single 
nucleotide polymorphisms on chromosome 9p21 were found to be 
related to coronary atherosclerosis and myocardial infarction in 
different populations.7)8)
The first study describing two of these polymorphisms 
(rs10757274 and rs2383206) on chromosome 9p21 associated with 
CAD in a Canadian population.7) These findings were also confirmed 
in other ethnic groups from Europe, Far-East, Middle-East, and 
India.9-13) Furthermore, this relationship was independent of 
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traditional risk factors for CAD. The single nucleotide polymorphism 
(SNP) on chromosome 9p21 was also associated with early onset of 
CAD, with a 2 fold increased risk of premature CAD.7)14) This genetic 
variant contributes to the risk of other atherosclerotic diseases 
such as aortic aneurysms and vascular dementia.15)16) However, 
in an African population, these associations were not detected, 
indicating other confounding mechanisms may alter the impact 
of these genetic variants on CAD development.17) The impact of 
the 9p21 locus on coronary artery disease severity and outcomes 
in patients with CAD has been studied by several researchers. 
However, results from these trials are contradictory.18) Thus, in the 
present study we aimed to investigate the impact of rs10757274 
and rs2383206 polymorphisms in the chromosome 9p21 on the 
presence and severity of coronary atherosclerosis in a Turkish 
population.
Subjects and Methods
Study design
This was a single-center, prospective and cross-sectional study. 
Power analyses were performed using the program of G*Power 
Version 3.1.9.2 (HHU, Düsseldorf Universitat, Germany) power-
and-sample size calculation (Düsseldorf Universität, Germany). 
Accordingly, (with an effective size w=0.3, α- error value of 0.05 
and a power of 0.95, and critical χ²=11.070) the minimum total 
sample size was 220. We had an opportunity to pool blood of 703 
consecutive patients who underwent coronary angiography (CAG) 
and 646 eligible patients were analysed. In order to increase the 
actual power of the study, we kept a large number of patients. Our 
study was conducted in accordance with the guidelines proposed 
in the Helsinki Declaration and approved by local ethical committee. 
All the patients gave informed consent before enrollment.
Study population and basal characteristics
Six hundred forty six consecutive patients who referred to 
coronary angiography by the indication of positive stress test or 
clinical highly suspicion of coronary artery disease on an outpatient 
clinic basis at our cardiology department had been involved in 
this prospective study. Exclusion criteria were unstable coronary 
syndromes, severe valvular diseases, decompensated heart 
failure, malignancy, renal or hepatic dysfunction, acute or chronic 
infection, hematologic and rheumatologic diseases, severe chronic 
obstructive lung disease. The patients who had revascularization 
(percutaneous coronary intervention or coronary artery bypass 
graft operation) history or technically inadequate coronary 
angiograms were also excluded because calculation of Gensini 
score is not possible in such cases. 
Basal characteristics of the study patients were reviewed. 
Hypertension was defined as being under active antihypertensive 
treatment or documentation of blood pressure more than 140/90 
mmHg. Diabetes mellitus was defined as fasting glucose level 
of ≥126 mg/dL and/or glucose level of ≥200 mg/dL at any time 
or active use of antidiabetic treatment. Smoking was defined as 
current smoking. The family history of coronary artery disease 
was accepted as positive if the patient had a first-degree relative 
who had myocardial infarction, sudden death, or revascularization 
before the age of 45 for men and 55 for women. We measured 
height and weight in every patient to determine body-mass index. 
Blood sample for analysis of blood glucose, renal function tests 
and lipid profile and genetic analysis had been drawn before 
coronary angiography. We performed coronary angiography using 
Judkins technique. All of the angiograms were reviewed by an 
independent, invasive cardiologist for the presence of CAD. The 
number of the coronary arteries with >50% stenosis, coronary 
vessel score was determined. Patients were divided into two groups 
with respect to coronary vessel score. Patients with vessel score>0 
were included in the group of CAD (n=352) and patients with 
vessel score=0 were included in the control group. The severity 
of coronary atherosclerosis was determined by Gensini’s score 
which considers both the extent and the severity of the lesions in 
a coronary angiography.19) This scoring system grades the stenosis 
in the epicardial coronary arteries (1 for 1-25% stenosis, 2 for 26-
50% stenosis, 4 for 51-75% stenosis, 8 for 76-90% stenosis, 16 
for 91-99% stenosis, and 32 for total occlusion) and multiplies this 
number by a constant number, which is determined according to the 
anatomical position of the lesion. Polymorphism-1 term was used 
for “rs10757274” and polymorphism -2 was used for “rs2383206”. 
Alleles of AA, AG and GG were determined for each gene.  
Genetic analysis
Genomic DNA was extracted from the peripheral blood of the 
study subjects using an extraction kit (Heliosis, Metis Biotechnology, 
Ankara, Turkey) according to the manufacturer’s instructions. Two 
polymorphisms, named rs10757274 and rs2383206, were screened 
using polymerase chain reaction - restriction fragments length 
polymorphism method. A specific primer pair was designed for 
both polymorphism using Primer Premier 5 Software (Premier 
Biosoft International, CA, USA).
Briefly, 401 bp DNA fragment containing the region of 
rs10757274 polymorpism was amplified with the primers: 
forward 5’-GCTTCTCCCCCGTGGGTCAAATCT-3’; and reverse 
5’-AATGAGGGGAGGGAGCATGTCTGT-3’. For the rs2383206 
polymorphism, polymerase chain reaction (PCR). reaction was 
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performed to amplify a 270-bp fragment with the primers: 
forward 5’-GGATTATTGGTGGTTTTCTAG-3’; and reverse 
5’-CAAGACATAACTAATGGCTGAA-3’. Reaction conditions for these 
polymorphisms were as follows: initial denaturation at 94°C for 5 
min and 30 cycles of denaturation at 94°C for 30 seconds, annealing 
at 62°C for 1 min, extension at 72°C for 1 min, and final extension 
at 72°C for 5 minutes. PCR was performed using Eppendorf thermal 
cycler (Eppendorf, Hamburg, Germany).
After amplification, the PCR products were digested overnight 
with BsmAI (Fermentas, Germany ) for the rs10757274 polymorpism 
and AluI for the rs2383206 polymorphism. After digestion with 
BsmAI, 401 bp PCR product was cut into 370 and 31 bp fragments 
in the presence of A allele, whereas G allele was undigested. After 
digestion with AluI (Fermentas, Germany ), 270 bp PCR product was 
digested into 233 and 44 bp fragments in the presence of A allele, 
whereas the G allele remained undigested. DNA fragments were 
separated in 2% agarose gel stained with ethidium bromide, and 
were visualized by Gel Logic 100 Imaging System (GL 100; Kodak, 
Rochester, New York, NY, USA). The results were evaluated with two 
blind observers after image capturing.
Statistical analysis
The SPSS statistical software package (PASW Statistics for 
Windows, Version 18.0; SPSS Inc., Chicago, IL, USA ) was used for 
statistical analyses. Normality test for distribution of the continuous 
variables was performed using Kolmogorov-Smirnov test and 
histograms. Continuous variables presented as mean±standard 
deviation  and were compared with a t-test or one-way analysis of 
variance  and post-hoc comparisons were performed using Tukey’s 
test. Other abnormally distributed data were presented using 
median with 25th and 75th percentiles and compared with Kruskal-
Wallis test and the Mann Whitney U test was utilized for post-hoc 
pairwise comparisons. Categorical data was presented as numbers 
and percentages and compared using the Chi-square test (Fisher 
exact test, if needed). The potential confounders of CAD were first 
evaluated by univariate regression analysis and variables with a p 
of <0.1 were together recruited in a multivariate logistic regression 
model to find out the independent predictors of the presence of 
CAD. A p<0.05 was considered statistically significant. 
Results
 
Of 646 consecutive patients, 240 female (37.2%) and  406 male 
(62.8%) with a mean age of 58.12±11.06 were included in the study. 
When the baseline characteristics of the patients were considered, 
356 of them (55.1%) were hypertensive, 170 were diabetic (26.3%) 
264 patients were current smokers (40.9%), and 177 patients had 
a positive family history of premature atherosclerotic CAD (Table 1). 
Laboratory findings of the patients are presented in Table 1. The 
distribution of the alleles was as follows; AA 12.1%, AG 42.3 %, 
GG 45.7% in gene-1, and AA 17%, AG 50.2%, GG 32.8% in gene-
2 (Table 1). The Gensini score of the patients ranged between 0 
and 202 with a median value of 9 (0-36). When the presence of 
the CAD between the alleles were compared in polymorphism-1, 
there was a significant difference between the alleles (38.9% in AA, 
48.0% in GG and 56.4% in AG, p=0.017). However, there was not 
any difference between the alleles in polymorphism-2. The patients 
were divided into CAD (vessel score>0) and a control group and 
the baseline characteristics, laboratory findings and genetic results 
were presented in Table 2. According to the vessel scores, there was 
a significant difference between the alleles in polymorphism-1 (AA 
0.71±1.04, GG 0.88±1.07, AG 1.06±1.12, p=0.018) (Fig. 1). 
Post-hoc comparisons revealed a significant difference between 
the alleles of AA and AG (p=0.01). In polymorphism-2, vessel 
Table 1. The baseline characteristics of the entire study population 
(n=646)
Parameters Study participants
Age (years) 58.12±11.06
Female/male (n) 240/406
Hypertension (%) 55.1
Diabetes mellitus (%) 26.3
Smoking (%) 40.9
Family history of CAD (%) 27.4
Body mass index (kg/m2) 28.93±5.39
Total cholesterol (mg/dL) 195.18±48.77
LDL-C (mg/dL) 121.25±40.29
HDL-C (mg/dL) 42.58±11.62
Triglycerides (mg/dL) 134 (99-190)
Creatinine (mg/dL) 0.90±0.27
Gensini score (n) 9 (0-36)
Alleles-gene 1 (%)
AA 12.0
AG 42.3
GG 45.7
Alleles-gene 2 (%)
AA 17.0
AG 50.2
GG 32.8
Data are given as mean±standard deviation, median (interquartile range) 
or n (%). CAD: coronary artery disease, HDL-C: high density lipoprotein 
cholesterol, LDL-C: low density lipoprotein cholesterol 
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scores were comparable between the alleles. In polymorphism-1, 
there was a significant difference in term of CAD extent estimated 
by Gensini score (p=0.041). In post-hoc comparisons, there was 
no difference in Gensini score between AA and GG (p=0.42). A 
difference was evident between GG and AG (p=0.04), as well as 
between AA and AG (p=0.035). Gensini scores did not differ 
between the alleles in polymorphism-2 (p>0.05 for all). The 
parameters used for evaluating of presence and extent of CAD 
in different alleles in polymorphism-1 were presented in Table 3. 
There were no differences in baseline characteristics and laboratory 
parameters between the alleles in polymorphism-1 (Table 4). A 
logistic regression analysis including all the potential confounders 
was used to search the independent predictors of the presence of 
CAD (vessel score>0). Age, male sex, diabetes mellitus, smoking, 
LDL cholesterol and creatinine levels were found to be independent 
predictors of the presence of CAD (Table 5). Multivariate stepwise 
linear regression analysis showed that age (p<0.001), male gender 
(p<0.001), diabetes (p=0.002), family history of CAD (p=0.035) and 
serum creatinine levels (0.018) were independent factors of the 
extent of CAD estimated by Gensini score.
Discussion
Several studies showed that the polymorphisms located on 
chromosome 9p21 have different impacts on predisposition to 
CAD in different ethnic groups.7)9-13) In this study, we evaluated the 
importance of these polymorphisms in a Turkish population, and 
showed that AG allele for “rs10757274” on chromosome 9p21 locus 
may have a role in progression of CAD. The number of patients with 
CAD was higher among the group including the patients carrying 
this allele. Moreover, the angiographic severity of CAD was higher 
in patients with this allele. However, the relationship with this 
genetic feature and coronary atherosclerosis was not independent 
of traditional risk factors for CAD.  
Table 3. Comparison of presence and extent of coronary artery disease 
between alleles in gene-1 
Variables AA AG GG         p
Presence of CAD (%) 38.9 56.4 48.0 0.017*
Vessel score 0.71±1.04 0.88±1.07 1.06±1.12  0.018†
Gensini score 5 (0-27) 15 (1-40) 7 (0-33) 0.041†
Data are given as mean±standard deviation, median (interquartile range) 
or n (%). CAD: coronary artery disease. *Chi-square test, †Kruskal-Wallis 
test, post-hoc tests revealed significant differences between AA and AG for 
vessel score (p=0.01) and between GG -AG (p=0.04) and AA-AG (p=0.035) 
for Gensini score
Table 2. Comparison of baseline characteristics of the CAD patients and 
control subjects
Parameters CAD (n=352) Control (n=294) p
Age (years) 60.46±10.57 55.34±11.00 <0.001
Male gender (%) 74.1 49.3 <0.001
Hypertension (%) 62.8 53.3 0.02
Diabetes mellitus (%) 34.4 20.0 <0.001
Smoking (%) 49.8 36.3 0.001
Family history of CAD (%) 27.6 31.5 0.32
Body mass index (kg/m2) 28.30±4.97 29.63±5.75 0.01
LDL-C (mg/dL) 116.25±40.75 127.37±38.93 0.001
HDL-C (mg/dL) 40.38±10.44 45.31±12.43 <0.001
Triglycerides (mg/dL) 164.09±113.29 151.09±78.49 0.1
Creatinine (mg/dL) 0.96±0.32 0.83±0.18 <0.001
Alleles-gene 1 (%)
AA 9.7 15.0
AG 46.6 37.1
GG 43.8 48.0 0.02*
Alleles-gene 2 (%)
AA 15.3 19.0
AG 51.1 49.0
GG 33.5 32.0 0.46 
Data are given as mean±standard deviation, median (interquartile range) 
or n (%). *p between all Alleles  (p=0.20 between AA and GG Alleles; p=0.06 
between AG and GG Alleles; p=0.014 between AA and AG Alleles). CAD: 
coronary artery disease, HDL-C: high density lipoprotein cholesterol, LDL-
C: low density lipoprotein cholesterol 
Fig. 1. Comparison of vessel scores between alleles in gene 1. Note that 
the vessel scores were 0.71±1.04 in AA, 0.88±1.07 in AG and 1.06±1.12 in 
GG allel (between three groups, p=0.018). Pairwise comparisons are 
presented. 
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Although CAD is still the leading cause of death all over the 
world, a significant decrease in mortality has occurred in developed 
countries. This reduction in mortality is not only a result of modern 
therapy, but also due to effective control of cardiovascular risk 
factors.20) In an INTERHEART study,20) 90% of the cardiovascular 
mortality was found to be related with risk factors such as 
abnormal lipids, alcohol, smoking, hypertension, diabetes and 
abdominal obesity.20)21) Thus, identification of the all risk factors 
and their mechanisms has profound importance for the effective 
treatment and prevention of CAD. Now, sufficient amount of 
data indicates that genetic predisposition is an independent risk 
factor for CAD.5) GWAS have defined around 30 risk substitutes for 
CAD.22) These studies have demonstrated that the 9p21 locus may 
be characterized by an increased risk of CAD.23) 9p21 locus has been 
proposed to apply direct impacts on vascular wall independently 
other conventional risk factors and accelerate the atherosclerotic 
process.24) The mechanism of the 9p21 negotiates risk for CAD is 
still unclear. The closest genes which code proteins are the cyclin-
dependent kinase inhibitors CDKN2A/2B (rs10757274) that locate 
about 100000 base pairs upper parts of the 9p21 locus. CDKN2A 
and CDKN2B play an important role in cell proliferation and they 
are suppressed by Polycomb proteins during cell growth and then 
activated during senescence.25) antisense noncoding RNA in the 
INK4 locus (ANRIL) (known as CDKN2BAS) has been suggested 
to regulate senescence at the CDKN2A gene locus and it shows 
a senescence-dependant role in proliferation. Inhibition of ANRIL 
causes decrement proliferation of human fibroblasts. Reduced 
expression of ANRIL was associated with atherosclerosis.26) 
Transforming growth factor beta (TGFβ) is a cytokine that prevents 
macrophage foam cell formation. TGFβ initiates the expression 
of the CDKN2A and CDKN2B.27) These are just two of the TGFβ 
responsive genes that are sited in the environs and are directly 
under the control of the 9p21 genetic risk locus. SNPs such as 
rs1333045 that inhibit TGFβ responsive factors at the 9p21 locus 
and this may lead to the progression of atherosclerotic process.28) 
These genetic features may act to accelerate progression of 
atherosclerosis, induce plaque rupture or thrombogenesis. Given 
that they are acting through an unknown mechanism, which is 
independent of traditional risk factors, there may be new targets 
waiting to be identified in the future for more efficient treatment 
Table 4. Comparison of baseline characteristics between alleles in gene -1
Parameters AA (n=78) AG (n=273) GG (n=295) p
Age (years) 58.25±12.30 58.28±10.52 57.94±11.25 0.93
Female, n 38 (48.7) 92 (33.6) 110 (37.2) 0.053
Hypertension, n 46 (58.9) 165 (60.5) 166 (56.2) 0.58
Diabetes mellitus, n 17 (21.8) 84 (30.7) 79 (26.8) 0.31
Smoking, n 29 (37.1) 124 (45.4) 130 (43.9) 0.53
Family history of CAD, n 23 (29.4) 81 (29.7) 85 (28.8) 0.97
Body mass index (kg/m2) 28.79±5.74 28.84±4.82 29.06±5.80 0.90
Total cholesterol (mg/dL) 189.72±48.74 192.79±46.99 198.75±50.26 0.21
LDL-C (mg/dL) 117.45±36.75 120.19±40.01 123.20±40.54 0.47
HDL-C (mg/dL) 44.36±11.35 42.31±11.53 42.37±11.75 0.37
Triglycerides (mg/dL) 132 (89-185) 131 (104-189) 140 (99-196) 0.53
Creatinine (mg/dL) 0.85±0.23 0.92±0.29 0.89±0.27 0.12
Data are given as mean±standard deviation, median (interquartile range) or n (%). CAD: coronary artery disease, HDL-C: high density lipoprotein cholesterol, 
LDL-C: low density lipoprotein cholesterol 
Table 5. Multivariate logistic regression analysis to determine the 
independent predictors of the presence of coronary artery disease
Variables Odds ratio 95% CI p
Age 1.055 1.034-1.076 <0.001
Male 3.137 1.891-5.206 <0.001
Hypertension 1.377 0.893-2.124 0.147
Diabetes mellitus 1.698 1.070-2.696 0.025
Smoking 1.595 1.023-2.487 0.039
Family history of CAD 1.142 0.731-1.786 0.559
LDL-C 0.994 0.989-0.999 0.024
Creatinine 3.222 1.101-9.340 0.033
AG allele in gene-1 1.304 0.876-1.943 0.191
CI: confidence interval, CAD: coronary artery disease, LDL-C: low density li-
poprotein cholesterol
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or prevention strategies to control CAD epidemics. 
Data analysis of The Wellcome Trust-Case Control Consortium 
study and German Myocardial Infarction Family Study has detected 
supplemental loci at 9p21, 6q25.1and 2q36.3 as loci for risk 
augmentation for CAD with the main SNPs; existing rs1333049, 
rs6922269, and rs2943634 respectively.9)  Similar relationships with 
SNPs and 9p21 locus has been shown in Canadians (rs10757274, 
rs2383206), Icelanders (rs1333040, rs23833207, rs10116277 and 
rs10757278).7)8) Munir et al.18) displayed a relation of 9p21-3 allele 
with an increased risk of triple vessel disease and severity of 
atherosclerosis burden measured with the Gensini score in a meta-
analysis.
In a very recent study performed by Çakmak et al.,29) the two 
SNPs of rs2383207 and rs1333049 at the 9p21 chromosome 
were evaluated  in 220 patients with CAD in a Turkish population. 
Significant differences were seen in frequencies of rs2383207 and 
rs1333049 variants between CAD patients and healthy subjects. 
Also, for the two SNPs, the risk genotypes AA and GG were related 
with an increased risk of CAD. Furthermore, AA genotype was an 
independent predictor of CAD. Although our study population 
was similar in terms of race and ethnicity, there are important 
differences between the two studies. We investigated different 
SNPs (rs10757274 and rs2383206 polymorphisms) on the same 
chromosome of 9p21. Our study population was wider and 
patient selection showed important discrepancies between the 
two studies. Çakmak et al.29) did not include patients older than 
55 years in male -and 65 years in female patients. However, these 
gene polymorphisms are particularly expected to be related with 
premature atherosclerosis. Additionally, they accepted patients 
having a coronary lesion less than 70% as control subjects. 
Because CAG is a luminographic method many patients might have 
been under-diagnosed when calculating the vessel score. Finally, 
they have not mentioned if patients with coronary stents and/or 
coronary grafts were excluded from the study. This is important 
since the Gensini score cannot be calculated in such patients. 
When our study considered the rs10757274 polymorphism, the risk 
genotype of AG was related with an increased number of vessel 
score. However, none of the alleles were independent predictors of 
either presence or extent of CAD. This result can be explained by 
complex interaction between all confounders for development and 
progression of CAD. 
In contrast to previous studies indicating an independent 
relationship between polymorphisms on 9p21 gene and CAD, our 
findings showed that the relationship was associated with traditional 
risk factors. Thus, these polymorphisms may also be associated 
with risk factors affecting CAD development such as hypertension, 
diabetes or hyperlipidemia and may potentiate or accelerate their 
adverse effects on the coronary vessel wall. So, they may exert 
their effect through accelerating progression of atherosclerosis. 
This theory could also explain the relationship between these 
polymorphisms and premature onset-CAD. Coronary artery disease 
is also the leading cause of death in Turkish population and the mean 
age for CAD is relative younger compared to other populations.30) 
In addition, the finding of increased angiographic severity of CAD, 
which is determined by Gensini score in our study, also supports 
this theory. Further studies on larger populations are required to 
clarify these mechanisms. LDL cholesterol level was lower in CAD 
group compared to control group. This result was driven by higher 
use of statins in the CAD group. In the CAD group, patients with 
a prior diagnosis of CAD had, as expected, hypertension, diabetes, 
smoking, male gender and elderly patients were more common, 
all of which were associated with higher CAD risk score and more 
extent use of statins.
The main limitations of our study are the cross-sectional nature 
and relatively small number of the study population. Second, it was 
a single-center study. Third, we investigated only two SNPs though 
there are many remarkable SNPs associated with CAD. Although 
the present study was not designed to show the pathophysiological 
mechanisms which are responsible for the adverse effects of 
these genetic polymorphisms, the findings of an increase in the 
Gensini score with an AG allele for gene-1 and the dependence on 
traditional risk factors indicate that the mechanism of action may 
accelerate and/or facilitate coronary atherosclerosis. Our study 
paves the way for performing larger studies on this issue.
In conclusion, our findings showed that the presence of 
polymorphism, including AG allele on chromosome 9p21, was 
related to CAD in a Turkish population. Although this relationship 
was not independent of other cardiovascular risk factors, this 
genetic feature may potentiate or accelerate their adverse effects 
on cardiovascular system. This relationship may explain the high 
mortality and morbidity caused by CAD in this Turkish population. 
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